Literature DB >> 31655714

Insulin Pumps: Review of Technological Advancement in Diabetes Management.

Nicoleta D Sora1, Fnu Shashpal2, Elizabeth A Bond2, Alicia J Jenkins3.   

Abstract

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII) therapy is an evolving form of insulin delivery which has been shown to be highly effective in maintaining euglycemia and providing patients with flexibility in their lives. It functions by providing the patient with a continuous subcutaneous infusion of a rapid acting insulin and allows the patient to administer boluses throughout the day for food and correction of high glucose levels. CSII is approved in patients with type 1 diabetes and selected patients with type 2 diabetes; however, it is important to select the right patients for pump therapy. Insulin pump technology continues to rapidly evolve, and many options are now on the market, including those that are used in conjunction with continuous glucose monitoring. This review article focuses on the pros and cons of CSII therapy as well as the technical and clinical considerations in starting a patient on this therapy. Published by Elsevier Inc.

Entities:  

Keywords:  Continuous subcutaneous insulin infusion; Diabetes mellitus; Hypoglycemia; Insulin pump; Multiple dose injections

Year:  2019        PMID: 31655714     DOI: 10.1016/j.amjms.2019.08.008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

1.  The diabetes quality of life brief clinical inventory in combination with the management strategies in type 1 diabetes mellitus with or without the use of insulin pump.

Authors:  Emmanouil S Benioudakis; Evangelos D Georgiou; Eirini D Barouxi; Athanasios M Armagos; Vaia Koutsoumani; Faidra Anastasiou-Veneti; Eleni Koutsoumani; Maria Brokalaki
Journal:  Diabetol Int       Date:  2020-11-16

Review 2.  Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches.

Authors:  Murugan Prasathkumar; Robert Becky; Salim Anisha; Chenthamara Dhrisya; Subramaniam Sadhasivam
Journal:  Biotechnol Lett       Date:  2022-02-04       Impact factor: 2.461

Review 3.  Review of Modern Insulin Pumps and the Perioperative Management of the Type 1 Diabetic Patient for Ambulatory Dental Surgery.

Authors:  Philip M Yen; Andrew S Young
Journal:  Anesth Prog       Date:  2021-10-01

4.  Circular RNA circVEGFC accelerates high glucose-induced vascular endothelial cells apoptosis through miR-338-3p/HIF-1α/VEGFA axis.

Authors:  Hua Wei; Cong Cao; Xiaojuan Wei; Minglv Meng; Biaoliang Wu; Lianxin Meng; Xi Wei; Shixing Gu; Hongmian Li
Journal:  Aging (Albany NY)       Date:  2020-07-17       Impact factor: 5.682

5.  Clinical Outcome and Cost-Effectiveness Analysis of CSII Versus MDI in Children and Adolescent With Type 1 Diabetes Mellitus in a Public Health Care System of China.

Authors:  Sicui Hu; Hongxiu Yang; Zhihong Chen; Xuefei Leng; Cheng Li; Lingyan Qiao; Weiqing Lv; Tang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-30       Impact factor: 5.555

Review 6.  Diabetology 4.0: Scoping Review of Novel Insights and Possibilities Offered by Digitalization.

Authors:  Claudia Eberle; Stefanie Stichling; Maxine Löhnert
Journal:  J Med Internet Res       Date:  2021-03-24       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.